Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.53 |
| ▸ | BMP1 | P13497 | 2/20 | 0.49 |
| ▸ | PLG | P00747 | 3/20 | 0.48 |
| ▸ | HPN | P05981 | 2/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.48 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | NPY4R | P50391 | 4/20 | 0.47 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | NPY1R | P25929 | 3/20 | 0.47 |
| ▸ | NPY2R | P49146 | 3/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123004 | 0.91 | NPY4R (0.46) | F2PLGHPNST14HGFAC | |
| SCHEMBL7534730 | 0.90 | BMP1 (0.51) | F2BMP1NPY5RNPY4RNPY1R | |
| SCHEMBL2922115 | 0.89 | NPY4R (0.49) | F2BMP1NPY5RNPY4RNPY1R | |
| SCHEMBL2921577 | 0.89 | MMP2 (0.55) | F2BMP1NPY5RNPY4RNPY1R | |
| SCHEMBL7752667 | 0.85 | SLC1A3 (0.52) | F2PLGHPNST14HGFAC | |
| SCHEMBL4642667 | 0.85 | NPY5R (0.52) | F2PLGNPY5RNPY4RF10 | |
| SCHEMBL7125358 | 0.82 | NPY4R (0.51) | F2PLGNPY5RNPY4RF10 | |
| SCHEMBL2927549 | 0.82 | F10 (0.54) | F2PLGHPNST14HGFAC | |
| SCHEMBL5780617 | 0.81 | F2 (0.61) | F2PLGNPY5RF10PLAU | |
| SCHEMBL6551485 | 0.81 | MC4R (0.57) | NPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675824-B1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | WURSTER SIEGFRIED (FI) | 2010-09-29 | — | — | EP | disclosed |
| US-20030144310-A1 | Molecules specific for NPFF receptors and uses thereof | H. LUNDBECK A/S (DK) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144310-A1 | Molecules specific for NPFF receptors and uses thereof | NPFFR1, NPFFR2, NPBWR1 | F2 3607/4885BMP1 1790/4885PLG 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.